Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Mobilização Precoce Assistida por Doppler em Adultos após Acidente Vascular Cerebral Isquémico Agudo (DOP-MOBILIZE)

27 de setembro de 2026 atualizado por: João Sargento Freitas, Unidade Local de Saúde de Coimbra, EPE

Mobilização Precoce Assistida por Doppler em Adultos Após Acidente Vascular Cerebral Isquémico Agudo - um Ensaio Clínico Randomizado

Post-stroke mobilization remains a subject of ongoing debate. While early mobilization-particularly the first out-of-bed mobilization-has been associated with reduced systemic complications and earlier rehabilitation, it also carries potential risks, such as neurological deterioration in the presence of hemodynamic instability.

In this study, the primary aim is to investigate whether early mobilization, guided by hemodynamic evaluation after acute ischemic stroke offers superior outcomes compared to standard clinical care.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Cerebrovascular diseases are the leading cause of death in Portugal and one of the most significant contributors to morbidity and disability.

Early mobilization after stroke is debated due to its potential benefits-such as fewer systemic complications and faster rehabilitation-and risks, particularly in patients with hemodynamic instability.

International guidelines support for early mobilization tailored to the patient's neurological status; however, the scientific evidence remains limited, resulting in heterogeneous practices across institutions.

Previous studies have highlighted the insufficient consideration of hemodynamic status when determining the timing of initial mobilization.

This study is a phase 3, pragmatic, prospective, multicenter randomized controlled trial with blinded outcome assessment (PROBE design: Prospective, Randomized, Open-label, Blinded Outcome Assessment), with an anticipated total duration of 36 months.

The study will be conducted in the Neurology Departments of the participating hospital centers and aims to: (1) evaluate the superiority of early mobilization guided by hemodynamic assessment following acute ischemic stroke, compared to standard clinical practice; (2) assess neurological deficits, quality of life, and cognitive function at three months, as well as hospital length of stay, blood pressure profile evolution, patient-reported outcome measures (PROMs), and employability; (3) compare adverse events between patients undergoing Doppler-guided early mobilization and those in the control group, including hospital-acquired infections, neurological deterioration, hemorrhagic transformation, and mortality.

Patients randomized to the intervention group will be mobilized according to carotid and transcranial Doppler ultrasound findings. In the presence of hemodynamic impairment, patients will undergo progressive mobilization, aiming to be out of bed by days 5 to 7 post-stroke, with gait training as neurologically feasible. In the absence of such findings, patients will begin mobilization immediately after the examination, with the goal of being out of bed and seated within 48 hours, including gait training when possible. Functional status at three months will be assessed using the modified Rankin Scale (mRS), which constitutes the study's primary endpoint.

All data collection procedures will follow formal and ethical research standards, ensuring that all informed participants voluntarily, anonymously, consent to take part in the study, with confidentiality maintained and no costs or harm to participants.

Tipo de estudo

Intervencional

Inscrição (Estimado)

1300

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Clinical Trials Unit - Coimbra Academic Clinical Center CTU-CACC Unidade Local de Saude de Coimbra
  • Número de telefone: 8408 +351 239 400 400
  • E-mail: ctu-cacc@ulscoimbra.min-saude.pt

Locais de estudo

  • Croácia
  • Portugal
    • Coimbra District
      • Coimbra, Coimbra District, Portugal, 3004-561
        • Recrutamento
        • Unidade Local de Saude de Coimbra
        • Contato:
          • Clinical Trials Unit - Coimbra Academic Clinical Center CTU-CACC Unidade Local de Saude de Coimbra
          • Número de telefone: 8408 +351 239 400 400
          • E-mail: ctu-cacc@ulscoimbra.min-saude.pt
        • Investigador principal:
          • Joao Sargento Freitas, MD, PhD
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1649-028
        • Ainda não está recrutando
        • Unidade Local de Saúde de Santa Maria
        • Contato:
        • Contato:
          • Clinical Trials Unit - Coimbra Academic Clinical Center CTU-CACC
        • Investigador principal:
          • Ana Catarina Fonseca, MD
    • Matosinhos
      • Porto, Matosinhos, Portugal, 4464-513
    • Porto District
      • Porto, Porto District, Portugal, 4200-319
        • Ainda não está recrutando
        • Unidade Local de Saúde de São João
        • Contato:
          • Clinical Trials Unit - Coimbra Academic Clinical Center CTU-CACC
        • Contato:
        • Investigador principal:
          • Pedro Miguel Castro, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients diagnosed with ischemic stroke aged 18 years or older;
  • Ability to undergo carotid and transcranial Doppler ultrasound, as well as to mobilize within 48 hours;
  • Informed consent obtained from the patient or legal representative.

Exclusion Criteria:

  • Pre-existing disability with a modified Rankin Scale (mRS) score ≥ 4;
  • Diagnosis of Transient Ischemic Attack (TIA);
  • Severe hemodynamic instability, defined as:
  • Systolic blood pressure < 100 mmHg or > 220 mmHg;
  • Peripheral oxygen saturation < 92%;
  • Heart rate < 40 or > 112 beats per minute;
  • Body temperature > 38.5°C;
  • Neurological deterioration with altered level of consciousness (defined as Glasgow Coma Scale < 10);
  • Patients who underwent neurosurgical intervention within the past 30 days;
  • Concomitant diagnosis of a rapidly progressive fatal disease (e.g., terminal-stage cancer);
  • Requirement for continuous monitoring or continuous intravenous drug infusion;
  • Acute deep vein thrombosis/pulmonary embolism.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Doppler-guided early mobilization

Patients with ischemic stroke will be mobilized based on the results of carotid and transcranial Doppler ultrasound examinations. If significant hemodynamic alterations are identified, such as stenosis ≥70% or intracranial occlusions, mobilization will be gradually introduced up to the 5th-7th day post-event. In the absence of such alterations, mobilization will begin immediately, with out-of-bed transfer to a chair within 48 hours and gait training, if clinically feasible.
Procedimento: Doppler-guided early mobilization

Individualized early mobilization after ischemic stroke, guided by hemodynamic assessment using carotid and transcranial Doppler ultrasound. The type and timing of mobilization are adjusted according to the presence of significant hemodynamic alterations.
Sem intervenção: Standard Care Mobilization - Control Group

Patients with ischemic stroke are mobilized according to standard clinical practice, without considering hemodynamic assessment results from Doppler ultrasound. Mobilization is introduced gradually, guided by the patient's clinical tolerance.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Functional status at 3 months after ischemic stroke
Prazo: 3 months post-stroke

Functional status assessment at 3 months after ischemic stroke, using the modified Rankin Scale (mRS), analyzed on an ordinal scale (0-6), to measure the degree of dependence/functional impairment.

Score ranges:

0-no residual symptoms (better outcome);

  1. no significant disability;
  2. slight disability;
  3. moderate disability;
  4. moderately severe disability;
  5. severe disability;
  6. death (worse outcome).
3 months post-stroke

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Neurological Assessment (NIHSS Scale)
Prazo: Day 0, 48 hours, Day 7 and Month 3

Neurological assessment on the 7th day after ischemic stroke, measured using the National Institutes of Health Stroke Scale score (NIHSS, from 0-42) to evaluate the severity of neurological deficits.

Score ranges:

0-4: Minor Stroke (better outcome); 5-15: Moderate Stroke; 16-20: Moderate to Severe Stroke; 21-42: Severe Stroke (worse outcome).
Day 0, 48 hours, Day 7 and Month 3
Development of hospital-acquired infections
Prazo: Up to 7 days

Incidence of infections acquired during hospitalization
Up to 7 days
Vital signs - Body temperature
Prazo: Day 0, 48 hours, Day 7

Measurement of body temperature in degrees Celsius at the time of the visit
Day 0, 48 hours, Day 7
Vital signs - Systolic and diastolic blood pressure
Prazo: Day 0, 48 hours, Day 7

Measurement of blood pressure in mmHg at the time of the visit
Day 0, 48 hours, Day 7
Vital signs - Heart rate
Prazo: Day 0, 48 hours, Day 7

Measurement of heart rate in beats per minute (bpm) at the time of the visit
Day 0, 48 hours, Day 7
Mortality
Prazo: 3 months

Mortality rate (%)
3 months
EQ-5D-5L
Prazo: 3 months

An instrument to describe and value health across a wide range of disease areas.

5-level EQ-5D (EuroQol instrument with 5 dimensions and 5 levels) version with five dimensions (five levels, categorical options): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Score ranges:

  1. I have no problems ...walking/dressing, etc (better outcome);
  2. I have some problems ...walking/dressing, etc;
  3. I have moderate problems ...walking/dressing, etc;
  4. I have severe problems ...walking/dressing, etc;
  5. I have extreme problems ...walking/dressing, etc (worse outcome).
3 months
Recurrent stroke assessment
Prazo: Day 0, 48 hours, Day 7

Assessment of stroke recurrence after the first event, specifying the type into categories (no recurrence, new transient ischemic attack, new ischemic stroke, hemorrhagic stroke) and the time interval between events.
Day 0, 48 hours, Day 7
MONTREAL COGNITIVE ASSESSMENT (MoCA)
Prazo: Month 3

A brief cognitive screening tool used to assess mild cognitive impairment, score from 0-30.

Score ranges:

< 19: moderate to severe cognitive impairment (worse outcome); 19-25: mild cognitive impairment; > 26: normal (better outcome).
Month 3
Hospital Anxiety and Depression Scale (HADS)
Prazo: 3 months

Final score of the scale that assesses anxiety and depression in patients, especially those with physical illnesses (score from 0-21, wiht 14 items and each item with four-point scale, 0-3).

Score ranges:

0-7: Normal - No significant symptoms of anxiety or depression (better outcome); 8-10: Borderline/Mild - Presence of symptoms that may require attention; 11 or higher: Probable Case/Severe - Clinically significan psychological disorder or "probable case" (worse outcome).
3 months
Mobility assessment
Prazo: 48 hours, Day 7, Month 3.

Assessment of participant mobility according to categories (not yet mobilized, transfers to chair, ambulating)
48 hours, Day 7, Month 3.
Breath Holding Index (BHI) - measure 1
Prazo: Before 48 hours or Day 7 (if not performed previously)

Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels.

Three attempts will be performed for each participant with measurements of:

  • (a) baseline mean flow velocity before the apnea test (cm/sec)
Before 48 hours or Day 7 (if not performed previously)
Breath Holding Index (BHI) - measure 2
Prazo: Before 48 hours or Day 7 (if not performed previously)

Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels.

Three attempts will be performed for each participant with measurements of:

  • (b) mean flow velocity at the end of the apnea test (cm/sec).
Before 48 hours or Day 7 (if not performed previously)
Breath Holding Index (BHI) - measure 3
Prazo: Before 48 hours or Day 7 (if not performed previously)

Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels.

Three attempts will be performed for each participant with measurements of:

  • (c) apnea duration (sec).
Before 48 hours or Day 7 (if not performed previously)
Hemorrhagic transformation
Prazo: 48 hours, Day 7

Type of ischemic stroke complication according to hemorrhage infarction (HI) /parenchymal hemorrhage (PH) levels in brain tissue.

Score:

0- No complication HI1- Hemorrhage infarction 1; HI2- Hemorrhage infarction 2; PH1- Parenchymal hemorrhage 1; PH2- Parenchymal hemorrhage 2; No follow-up CT/MRI performed.
48 hours, Day 7
Early Mobilization Decision (<48h)
Prazo: Day 0

Ultrasound-guided (US) mobilization: early mobilization (<48h) if no cerebral hemodynamic impairment in US; Decision - yes or no? (only for interventional group)
Day 0
Hospitalization duration
Prazo: Month 3

Number of days of hospitalization
Month 3
White matter lesions in neuroimaging
Prazo: Day 0

White matter legions in neuroimaging - ARWMC scale: 0-no lesions (better outcome); 1-focal lesions; 2-beginning confluence of lesions; 3-diffuse involvement of the entire region, with or without involvement of U fibers (worse outcome).
Day 0

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Unidade Local de Saúde de Coimbra, EPE

Colaboradores

University Hospital Rijeka
Unidade Local de Saúde de Matosinhos, EPE
Klinički Bolnički Centar Zagreb
Unidade Local de Saúde Santa Maria
Unidade Local de Saúde de São José
Unidade Local de Saúde São João, Oporto

Investigadores

  • Investigador principal: Joao Sargento Freitas, MD, PhD, Unidade Local de Saude de Coimbra
  • Diretor de estudo: Joao Sargento Freitas, MD, PhD, Unidade Local de Saude de Coimbra

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de junho de 2025

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

16 de setembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de novembro de 2025

Primeira postagem (Real)

18 de novembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

29 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 197/24 CE

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Data will be irreversibly anonymized and exclusively handled by researchers involved in the study.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever